SCHEMBL13635997

SCHEMBL13635997

CCCN1CCN(C(=O)/C=C/c2ccccc2O)CC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.55
GPR183 P32249 2/20 0.51
NFKB1 P19838 2/20 0.50
JUN P05412 1/20 0.50
NFE2L2 Q16236 1/20 0.50
MAPT P10636 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
F2R P25116 1/20 0.48
POLB P06746 1/20 0.48
LMNA P02545 1/20 0.48
APP P05067 2/20 0.47
HPGD P15428 2/20 0.47
MEN1 O00255 2/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45
HRH3 Q9Y5N1 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ACHE P22303 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4379006 1.00 KMT2A (0.55) KMT2AGPR183NFKB1JUNNFE2L2
SCHEMBL13636157 0.87 APP (0.55) KMT2AGPR183MAPTL3MBTL1F2R
SCHEMBL4375996 0.87 APP (0.55) KMT2AGPR183MAPTL3MBTL1F2R
SCHEMBL4379116 0.86 MAPT (0.69) KMT2AGPR183NFE2L2MAPTL3MBTL1
SCHEMBL13636352 0.86 MAPT (0.69) KMT2AGPR183NFE2L2MAPTL3MBTL1
SCHEMBL4375435 0.84 KDM4E (0.64) KMT2AGPR183MAPTL3MBTL1F2R
SCHEMBL13636493 0.84 KDM4E (0.64) KMT2AGPR183MAPTL3MBTL1F2R
SCHEMBL13636224 0.82 KMT2A (0.83) KMT2AMAPTL3MBTL1POLBLMNA
SCHEMBL4384009 0.82 KMT2A (0.83) KMT2AMAPTL3MBTL1POLBLMNA
SCHEMBL12714221 0.80 HPGD (0.64) KMT2ANFKB1JUNNFE2L2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 KMT2A 295/4885GPR183 264/4885NFKB1 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.